Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 177,39 € ( 52,92 %). Der Median liegt bei 182,79 € ( 57,58 %).
Kaufen |
10 |
Halten |
1
|
Verkaufen |
0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 9 / 18 |
Levermann-Strategie | -7 / 13 |
Beliebteste Broker
News
- 30.09. - 12:30 Uhr
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD). » Mehr auf globenewswire.com
- 30.09. - 12:30 Uhr
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company's ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon™ PTH (palopegteriparatide; marketed as YORVIPATH®) through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population.1,2,3,4 In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency. » Mehr auf globenewswire.com
- 30.09. - 10:00 Uhr
Ascendant Resources Approved for EU Sponsored Cutting-Edge Geophysical "Undercover" Program at Its Lagoa Salgada Project
Lagoa Salgada selected to participate in the European Union's UNDERCOVER Project to unlock hidden critical mineral deposits at depth using cutting edge Geophysical techniques UNDERCOVER Project will employ Seismic Reflection and Refraction, Magnetotellurics (MT), Gravity and Magnetic Surveys, Electromagnetic (EM) Surveys, and Joint Inversion Techniques to delineate potential deposits of critical minerals at depth The two-year program is fully funded by the EU under its Horizon Program and is expected to commence in Q1 2025 TORONTO, ON / ACCESSWIRE / September 30, 2024 / Ascendant Resources Inc. (TSX:ASND), through its Portuguese subsidiary, Redcorp Empreendimentos Mineiros Lda is pleased to announce its award of EU funding through its participation in the UNDERCOVER project. The project aims to advance mineral exploration by applying state-of-the-art geophysical technologies to uncover hidden mineral deposits at significant depths. » Mehr auf accesswire.com
Unternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 36,18 Mio | 23,66% |
Bruttoeinkommen | 22,67 Mio | 34,23% |
Nettoeinkommen | 109,93 Mio | 9,47% |
EBITDA | 129,52 Mio | 20,06% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 6,65 Mrd € |
Anzahl Aktien | 57,35 Mio |
52 Wochen-Hoch/Tief | 150,15 € - 80,71 € |
Dividenden | Nein |
Beta | 0,65 |
KGV (PE Ratio) | 13,57 |
KGWV (PEG Ratio) | 5,01 |
KBV (PB Ratio) | 20,69 |
KUV (PS Ratio) | 20,92 |
Unternehmensprofil
Ascendis Pharma A/S, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung von Therapeutika für ungedeckte medizinische Bedürfnisse. Das Unternehmen bietet SKYTROFA für die Behandlung von Patienten mit Wachstumshormonmangel (GHD) an. Außerdem entwickelt es TransCon Growth Hormone (hGH) für pädiatrische GHD in Japan, TransCon hGH für Erwachsene mit GHD, TransCon Parathyroid Hormon für Hypoparathyreoidismus bei Erwachsenen und TransCon CNP für pädiatrische Achondroplasie. Darüber hinaus entwickelt das Unternehmen TransCon Toll Like Receptors 7/8 Agonist für die intratumorale Verabreichung und TransCon IL-2 ß/g für die systemische Verabreichung. Das Unternehmen wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Hellerup, Dänemark.
Name | Ascendis Pharma ADR |
CEO | Jan Moller Mikkelsen |
Sitz | Hellerup,
Dänemark |
Website | |
Industrie | Chemikalien |
Börsengang | 28.01.2015 |
Mitarbeiter | 879 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | ASND |
Frankfurt | A71.F |
Düsseldorf | A71.DU |
München | A71.MU |
Assets entdecken
Shareholder von Ascendis Pharma ADR investieren auch in folgende Assets